Sorry, you need to enable JavaScript to visit this website.

DAURISMO™ (glasdegib) Clinical Studies


The efficacy of DAURISMO in combination with low-dose cytarabine was evaluated in a multicenter, open-label, randomized study (Study BRIGHT AML 1003, NCT01546038) that included 115 patients age 55 years or older with newly-diagnosed AML who met at least one of the following criteria: a) age ≥ 75 years, b) severe cardiac disease, c) baseline Eastern Cooperative Oncology Group (ECOG) performance status of 2, or d) baseline serum creatinine >1.3 mg/dL. Patients were randomized 2:1 to receive DAURISMO at a 100 mg daily dose with low-dose cytarabine 20 mg subcutaneously twice daily on days 1 to 10 of a 28-day cycle (N=77) or low-dose cytarabine alone (N=38) in 28-day cycles until disease progression or unacceptable toxicity. Patients were stratified by cytogenetic risk (good/intermediate or poor).

The baseline demographic and disease characteristics are shown in Table 5. The two treatment arms were generally balanced with respect to the baseline demographics and disease characteristics (see Table 5).

Table 5. Baseline Demographic and Disease Characteristics in Patients with AML
Demographic and Disease Characteristics DAURISMO With Low-Dose Cytarabine
Low-Dose Cytarabine Alone
Abbreviations: AML = acute myeloid leukemia; N = number of patients; ECOG PS = Eastern Cooperative Oncology Group Performance Status.
Baseline ECOG PS was not reported for one patient in the DAURISMO with low-dose cytarabine arm.
Median (Min, Max) (Years) 77 (64, 92) 76 (58, 83)
≥ 75 years N (%) 47 (61) 23 (61)
Sex, N (%)
Male 59 (77) 23 (61)
Female 18 (23) 15 (39)
Race, N (%)
White 75 (97) 38 (100)
Black or African American 1 (1) 0 (0)
Asian 1 (1) 0 (0)
Disease History, N (%)
De Novo AML 38 (49) 18 (47)
Secondary AML 39 (51) 20 (53)
Prior Hypomethylating Agent Use 11 (14) 6 (16)
ECOG PS*, N (%)
0 to 1 35 (46) 20 (53)
2 41 (53) 18 (47)
Cytogenetic Risk Status, N (%)
Good/Intermediate 48 (62) 21 (55)
Poor 29 (38) 17 (45)
Baseline Severe Cardiac Disease 51 (66) 20 (53)
Baseline Serum Creatinine >1.3 mg/dL 15 (19) 5 (13)

Efficacy was established on the basis of overall survival (OS) from the date of randomization to death from any cause. With a median follow-up of approximately 20 months, the DAURISMO with low-dose cytarabine arm was superior to low-dose cytarabine alone arm (Figure 1). The efficacy results are shown in Table 6. Improvement in OS was consistent across prespecified cytogenetic risk subgroups.

Table 6. Efficacy Results From BRIGHT AML 1003
Endpoint/Study Population DAURISMO With Low-Dose Cytarabine Low-Dose Cytarabine Alone
Abbreviations: AML = acute myeloid leukemia; N = number of patients; OS = overall survival; CI = confidence interval; CR = complete response.
Hazard ratio (DAURISMO with low-dose cytarabine/low-dose cytarabine alone) based on the Cox Proportional hazards model stratified by cytogenetic risk.
1-sided p-value from log-rank test stratified by cytogenetic risk.
OS N=77 N=38
  Median survival, months (95% CI) 8.3 (4.4, 12.2) 4.3 (1.9, 5.7)
  Hazard ratio (95% CI)* 0.46 (0.30, 0.71)
  p-value 0.0002
CR N=14 N=1
  CR rate (in %, 95% CI) 18.2 (10.3, 28.6) 2.6 (0.1, 13.8)

Figure 1. BRIGHT AML 1003 – Kaplan-Meier Plot of Overall Survival for Patients with AML

Figure 1

Abbreviations: CI = confidence interval; OS = overall survival; LDAC = low-dose cytarabine.

What's New

No Current Announcements.

Therapeutic Area

Contact Pfizer Medical

Report an Adverse Event

Contact Pfizer

Need to report an Adverse Event, Side Effect or Product Quality Concern?

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: (800) 438-1985

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns at 1-800-FDA-1088 or

Have a Medical Question on a Pfizer Prescription Medicine?
Contact Pfizer Medical Information to speak with a professional regarding your medical question on a Pfizer prescription product: (800) 438-1985
Have a Question about Pfizer Clinical Trials?
If you are looking for information about Pfizer studies currently recruiting new patients in your area, you can begin your search on our website. For questions about a Pfizer Clinical Trial, call (800) 718-1021 or email [email protected]
Need Information on Pfizer’s Patient Assistance Programs?

Pfizer RxPathways® connects eligible patients, regardless of their insurance status, to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. For more information, please call (844) 989-7284 or visit

Eligible patients can register for valuable savings offers for nearly 40 brand name medications. Visit for more information.